Chapter 8: Targeted drug delivery strategies: Ligand-based approaches

Vandana V. Shirsath*[1, 2], Gitanjali S. Bhatjire*[1, 2], Priyanka P. Thore[1], Vaishali Naphade, Anil G. Jadhav[1]

[1]*Mahavir Institute of Pharmacy, Nashik, Maharashtra, India, 422007*

[2]*School of Pharmacy, P. P. Savani university, Surat, Gujarat 394125, India*

Abstract: Targeted drug delivery systems represent a significant advancement in pharmacology, providing improved therapeutic efficacy while minimizing systemic toxicity. Among various targeting methodologies, ligand-based approaches have demonstrated significant promise due to their specificity, adaptability, and potential for clinical translation. Particular attention is given to the mechanisms of ligand-receptor interactions, conjugation techniques, and the challenges of optimizing binding affinity and internalization efficiency. Case studies highlight successful preclinical and clinical applications, especially in oncology and inflammatory diseases. Furthermore, the chapter addresses current limitations, such as off-target effects, immunogenicity, and scalability, while outlining future directions for improving selectivity and therapeutic outcomes through rational ligand design and nanotechnology integration. Overall, this comprehensive overview provides insights into the role of ligand-based targeting in advancing precision medicine.

keywords : Targeted drug delivery, Ligand-based targeting, Receptor-mediated delivery, Nanocarriers, Drug conjugates, Antibodies, Peptides

Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-674-4_8

Introduction:

Targeted Drug Delivery System It Is Define As It Is A Method In Which Increase The Concentration Of Medicine Or Medicament In Particular Tissue, Components And Organ, It Is Also Called As Smart Drug Delivery System. These nanoparticles Filled with medicament and drugs and target to specify site of the body. Portions of the body where there is exclusively infected tissue, in this way keeping away from connection with solid tissue. (1)

Properties of Targeted Drug Delivary System

1. It should be non-toxic Biocompatible and Physiochemical stable in vivo and in vitro
2. It should have uniform Capillary Distribution
3. It should be Predictable and Controllable rate of Drug release
4. Drug release should not affect the Drug Deli vary
5. Biodegradable Carrier should be used that get readily eliminated from the body without causing any problem.(2)

Drug Administration Protocol may be simplified. Drug quantity may be reduced as well as the cost of therapies. Avoid First pass metabolism(1,2)

And the Disadvantage of the same will be as : Rapid clearance of Targeted Drug delivery system. (1)

The goal line of an effective delivery_system is to deliver the medication to its intended location. An excellent medication that is known to infiltrate the blood-brain barrier. Recently, the medication delivery mechanism has been greatly impacted by nanomedicine. It also has further uses in nanotechnology. Because nanoparticles are so tiny, they may be used to deliver medications that are poorly soluble in water. They can also help prevent the liver's first pass metabolism. Drugs delivered using nanotechnology may stay in the bloodstream for extended periods of time, reducing plasma level variations and, consequently, adverse effects.

The distribution of drugs occurs at the intersection of biology, chemistry, and medicine. In addition to the traditional elements of medicinal chemistry, this discipline need a thorough comprehension of the basic distinctions between healthy and sick cells. Although there are now several methods for doing so, identifying the variation in the expression levels of certain cell surface receptors on sick vs healthy cells is one of the most promising ways. An effective method of medication distribution is to use this distinction to make the distinction between a pathologic tissue and its healthy equivalent. High affinity ligands that target these elevated cell surface receptors were used in this class to transport medicines that would not otherwise be addressed. As a result, hundreds of ligand-drug conjugates based on antibodies and smaller molecules are being researched; some of them have already received approval for use in cancer

treatments. Many pharmaceutical firms are now searching for novel methods to work together after realizing the promise of ligand-targeted medication delivery. These sectors have looked to academia for innovative medication delivery ideas as a result of the increased scholarly interest in pharmaceutical research. There are few comparable trainings or courses in drug delivery, despite the fact that medicinal chemistry training has become common at academic institutions around the globe.

Now is a good moment to introduce academics and students to this emerging sector since more and more academic institutions are eager to work together on industry projects. It is wise to offer drug delivery courses, training, and research facilities to stay up with current developments in medicinal chemistry. This will equip the future generation of researchers with the necessary skills to conduct research and create "smart" pharmaceuticals. With that in mind, this course on ligand-targeted drug delivery is intended to give students a broad overview of both drug delivery in general and ligand-targeted drug delivery in particular. The course will cover the theoretical underpinnings and practical applications of ligand-targeted drug delivery, with an emphasis on organic chemistry and biochemistry, and is intended for instructors and students with a foundational grasp of these fields This course's primary goal is to provide insight into how to apply fundamental research in this area to clinical settings. (3) Drug targeting is likely motivated by the following factors: the ability to treat and prevent disease; pharmaceutical drug stability in conventional dosage forms; biopharmaceutical low absorption; high membrane binding; biological instability; short half; large volume of distribution; and low therapeutic index.

Approaches for targeting:

Only a tiny percentage of most therapeutic medicines make it to the afflicted organ or cell. Targeted drug_delivery lowers the relative concentration of medications in the remaining cells or tissues while delivering the medication to the affected tissue or cell. Targeting can be done primarily in two ways:

1a. Passive Targeting: This strategy relies on the duration of circulation to determine the effectiveness of therapeutic targeting. Clocking the drug carrier with a coating of any kind will do this. For this strategy relies on the duration of circulation to determine the effectiveness of therapeutic targeting. Clocking the drug carrier with a coating of any kind will do this. (van Vlerken et al., 2007).

This is predicated on the medication being inserted in regions surrounding the target of interest, such tumor tissue. The term "Enhanced Permeability Retention" (EPR) effect refers to all of these conditions. Every kind of medication delivery system carrier experiences this kind of targeting. It is defined as the buildup of a drug or drug carrier system at a particular location. Both a specific place and systemic circulation

are the targets of the medicine. Targeting occurs as a result of the body's innate reaction to the drug's physiochemical makeup.

1b. Active Targeting: It entails functionalizing the drug carrier in order to provide the material only to the site that corresponds to the carrier's architecture.

First order Targeting, Second order targeting, Third Order Targeting Difference Between Active and Passive Targeting is shown in table 1

2. Ligand-Mediated Targeting

Ligand-mediated targeting, is a sophisticated drug delivery strategy It makes use of ligands—biological or artificial compounds—such aggressive tissues or cancer cells. Monoclonal antibodies, peptides, aptamers, folic acid, transferrin, and tiny molecules like galactose or mannose are examples of common ligands. The ligand-receptor connection promotes cellular uptake and therapeutic effectiveness by facilitating endocytosis, also known as receptor-mediated internalization, of the drug-loaded carrier upon binding.

This method reduces systemic toxicity and off-target effects while simultaneously raising medication concentration at the diseased location. For targeted delivery in cancer, neurology, and infectious illnesses, ligand-functionalized nanoparticles, liposomes, dendrimers, and micelles have all been extensively studied. Despite its potential, challenges such as ligand stability, immunogenicity, and optimal ligand density on carrier surfaces require careful consideration during formulation design.

3. Physical Targeting

A biological target can be defined anytime physiological or energy-dependent targeting mechanisms cause accumulation of a drug in certain tissues or organs. Physical targeting uses external cues determine where the drug accumulates or is released.

Contents of thermoresponsive liposomes release when mild hyperthermia is applied to tumor sites. Magnetic nanoparticles react to external magnetic field control allowing them to concentrate in targeted areas such as the liver and tumor blood vessels. Drug release gets triggered via pH-sensitive polymers upon these polymers encounter acidic conditions in tumor microenvironments and endosomal acid compartments. What’s powerful about this targeting approach is that it can access hard-to-penetrate or sacred areas such as brain tissue (through magnetic targeting) and tumor cores (through ultrasound cavitation). The blending of physical targeting methods with biochemical

approaches has become popular for combination therapies as well for increased precision.

4. Inverse Targeting

Inverse targeting, in which the drug is actively targeted away from such sites (i.e., RES, liver, or spleen), where large particles like liposomes and nanoparticles tend to accumulate. This can be quite important when off-target organ uptake causes toxicity or depletes drug deposition at the target.

Such a strategy could potentially pre-saturate RES receptors with blank carriers or decoys before administration of the therapeutic nanocarrier, limiting off-target absorption. Surface modifications like PEGylation can be utilized to avoid immune detection and extend circulation time – the so-called "stealth" effect. Drugs with inverse targeting are more likely to reach the target passively or actively and are more bioavailable in the systemic circulation.

5. Dual Targeting

Dual targeting combines two or more targeting strategies within a single delivery platform to achieve synergistic localization and uptake at the disease site. This approach may involve:

- **Dual-ligand targeting**, where two distinct ligands are conjugated to the same nanocarrier, allowing it to recognize multiple receptors on a heterogeneous tumor population.
- **Biochemical and physical targeting**, such as combining pH-sensitive drug release with receptor-mediated endocytosis.
- **Organ and cellular targeting**, where the first targeting moiety guides the system to a specific organ, and the second ligand facilitates intracellular uptake.

Dual targeting enhances specificity, overcomes biological barriers, and reduces the risk of resistance.

This strategy is particularly effective in complex pathologies like cancer, where receptor expression is variable and tumor microenvironments are highly heterogeneous.

6. Reverse Targeting (Repeated)

[Note: Point 6 appears to repeat **Inverse Targeting**. If you meant a different concept (e.g., *Reverse Targeting* or a unique mechanism), please clarify. For now, here's a refined, extended version.]

Inverse (or Reverse) Targeting, as reiterated, represents a proactive strategy to minimize non-specific uptake and extend systemic circulation time. One evolving facet of this strategy is the **temporary immune shielding** technique, wherein carriers are cloaked in biomimetic coatings, such as cell membranes (e.g., RBC or platelet membranes), to deceive the immune system. These "camouflaged" systems can circulate longer and evade premature clearance.

Moreover, **target-shielding mechanisms** such as decoy receptors or competitive inhibitors are also employed to temporarily block undesirable binding sites, allowing the medicine selectively reach the intended target. This concept is crucial in treatments where specific organ toxicity (like hepatotoxicity in chemotherapies) must be avoided without compromising efficacy.

Table 5 Difference Between Active and Passive Targeting

Sr.no	Active Targeting	Passive Targeting
1.	It depends on size, shape, and Surface Charge on Nanoparticle	It depends affinity ligand, ligand receptor and antigen-antibody or another form of molecular reaction to bring nanoparticle home to the tissue
2	Delivary by enhanced Permeability and Retention factor in tumor, inflammation.	Improve potency expected by more focus and concentrated delivery
3.	More Potential Side effect and toxicities and higher cost.	Less potential side effect and toxicities excepted
4.	Less efforts to engineers synthesize	More challenging to synthesize nanoparticle within ligand attached
5.	Less selective	Highley Selective
6.	Restricted in use	Highley Versatile
7.	Alter the Drug Distribution in the body	Increase the cellular drug uptake by target cell

ESSENTIALS OF MAKING THE BEST LIGAND-TARGETED MEDICATION

Basics of the Fabrication of a Most Favorable Ligand-Targeted Drug

It is emerged as a cutting-edge approach in nanomedicine and targeted therapeutics. The fabrication of an effective ligand-targeted drug involves several crucial steps, each requiring careful consideration and optimization.

1. Selection of an Appropriate Ligand

A ligand is a molecule that binds specifically to a target receptor found abundantly on diseased cells (such as tumor or inflamed tissues) but minimally or not at all on healthy cells.

Key considerations in ligand selection:

- **Specificity**: The ligand must show high specificity toward the receptor of interest to ensure minimal off-target effects.
- **Affinity**: Strong binding affinity is essential for ensuring the ligand remains attached to the receptor long enough to facilitate drug internalization.
- **Stability and Compatibility**: The ligand should remain stable in systemic circulation and must not undergo rapid degradation or denaturation.
- **Low Immunogenicity**: Especially in repeated dosing, the ligand should not trigger significant immune responses.

2. Characterization of the Target Receptor

Before fabricating a targeted drug, a thorough understanding of the target receptor is essential. The receptor should ideally be overexpressed on pathological cells and absent or minimally expressed in healthy tissues.

Key parameters for receptor characterization:

- **Expression level**: Verified using techniques such as flow cytometry, Western blotting, immunohistochemistry (IHC), or PCR.
- **Internalization capability**: Determines whether the receptor facilitates the acceptance of the ligand-drug complex into the cell.
- **Accessibility**: The receptor must be present on the cell surface and accessible in the in vivo environment.
- **Selectivity**: It should distinguish between diseased and healthy tissues, thereby minimizing adverse effects.

3. Drug Conjugation Strategy

Conjugating the drug to the ligand is a central step in targeted drug design. The goal is to ensure the ligand retains its targeting ability while the drug remains pharmacologically active.

Types of conjugation:

- **Direct conjugation**: The drug is chemically linked to the ligand using functional groups (e.g., amine, carboxyl, thiol).
- **Carrier-mediated conjugation**: The ligand is attached to a nanoparticle or liposome, which in turn carries the drug.

Linkers used in conjugation can be:

- **Cleavable linkers**: Designed to break under specific conditions (e.g., acidic pH of tumor microenvironment, redox potential, or enzymatic cleavage).
- **Non-cleavable linkers**: Stable in the bloodstream, requiring cellular processing for drug release.

Example: In antibody-drug conjugates (ADCs), the cytotoxic drug is often attached via a linker that ensures drug release only after the complex is internalized by cancer cells.

4. Design of the Carrier System

In many cases, drugs are not directly conjugated to ligands but instead loaded into carrier systems that improve drug solubility, stability, and pharmacokinetics. These carriers serve as vehicles for controlled drug release and protection from premature degradation.

Common carriers include:

- Liposomes
- Polymeric nanoparticles (e.g., PLGA, PEG-PLA)
- Micelles
- Dendrimers
- Solid lipid nanoparticles (SLNs)

Design considerations:

- **Particle size**: Ideally between 10–200 nm to avoid renal_clearance and facilitate enhanced EPR in tumors.
- **Surface charge**: Slightly negative or neutral zeta potential helps reduce nonspecific interactions and prolongs circulation time.
- **Stealth characteristics**: Surface modifications like PEGylation help evade immune system clearance.
- **Biodegradability**: The material should degrade into non-toxic components after delivering the drug.

5. Ligand Density and Orientation

The number and positioning of ligands on the carrier surface influence the targeting efficiency. An optimal ligand density maximizes receptor binding without causing steric hindrance.

Challenges and optimization strategies:

- **Too many ligands**: Can lead to aggregation, reduced mobility, and poor receptor recognition.
- **Too few ligands**: Leads to poor targeting and uptake.
- **Random vs. site-specific conjugation**: Site-specific conjugation ensures uniform orientation and maximal binding efficiency.

- **Use of spacers**: Polyethylene glycol (PEG) spacers can be introduced between the carrier and the ligand to improve flexibility and access to the receptor.

Maintaining the **bioactive orientation** of the ligand is essential for effective receptor binding.

6. In Vitro and In Vivo Validation

Before clinical translation, rigorous testing is required to validate the efficiency and protection of the ligand-targeted drug system.

In vitro studies typically assess:

- Receptor binding affinity
- Cellular uptake/internalization (often visualized using fluorescence microscopy or flow cytometry)
- Cytotoxicity (MTT or similar assays)
- Specificity of uptake using receptor-positive and receptor-negative cells

In vivo studies evaluate:

- Biodistribution using radiolabels or fluorescent tags
- Tumor accumulation and clearance profiles
- Pharmacokinetic and pharmacodynamic (PK/PD) data
- Therapeutic efficacy and toxicity in animal models

Animal models should closely mimic the human disease pathology for predictive outcomes.

7. Scalability and Stability Considerations

For commercialization, the drug formulation must be amenable to **large-scale production** without loss of integrity, functionality, or therapeutic value.

Important parameters include:

- **Reproducibility**: Consistent particle size, ligand density, and drug loading must be ensured batch-to-batch.
- **Storage stability**: The formulation must retain its activity over time under storage conditions (temperature, humidity, light).
- **Regulatory compliance**: Manufacturing must follow Good Manufacturing Practices (GMP), and components should be pharmaceutically acceptable.
- **Sterilization**: Must not alter the physical or functional properties of the drug or carrier.
- **Cost-effectiveness**: The fabrication method should be economically viable for scaling and mass production.

Table 6 Marketed Products of Ligand Product Type/Remark of Ligand Company

Product	Type/Remark of Ligand	Company Name	Year of FDA Approval
Eloctate	Blood clotting factor (replacement therapy for hemophilia A)	Biogen Idec	2014
Alprolix	Blood clotting factor (replacement therapy for hemophilia B)	Biogen Idec	2014
Enbrel (etanercept)	Binds CD2 (inhibits T cell proliferation in psoriasis and transplant rejection)	Astellas and Biogen Idec	1998
Orencia (abatacept)	Binds CD80 and CD86 (inhibits T-cell co-stimulation in RA) Bristol-Myers-	Bristol-Myers- Squibb	2005
Nulojix (belatacept)	Binds CD80 and CD86 (inhibits T-cell co-stimulation in transplant rejection)	Regeneron and Sanofi Aventis 1	201
Zaltrap (Zivaflibercept)	Binds VEGF-A, VEGF-B, and PIGF (treatment of colorectal cancer	Regeneron and Sanofi Aventis	2012

Conclusion:

Compared to nontargeted methods, the ligand-targeted drug delivery system offers several benefits. Targeted medication delivery methods reduce undesirable toxicity by directing the therapeutic warhead precisely to the sick cell with the least amount of interaction with healthy, cells that function normally.

REFERENCE:

Devesh Kapoor, Shailendra Bhatt,Manish Kumar, Rahul Maheshwari3and Rakesh K. Tekade Basics Fundamental of drug delivary,Page no-307-308 doi.org/10.1016/B978-0-12-817909-3.00008-X

Drago J.Z., Modi S., Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat. Rev. Clin. Oncol. 2021;18:327–344. doi: 10.1038/s41571-021-00470-8.

Teicher B.A., Morris J. Antibody-drug Conjugate Targets, Drugs, and Linkers. Curr. Cancer Drug Targets. 2022;22:463–529. doi: 10.2174/1568009622666220224110538.

Tsuchikama K., An Z.Q. Antibody-drug conjugates: Recent advances in conjugation and linker chemistries. Protein Cell. 2018;9:33–46. doi: 10.1007/s13238-016-0323-0.

Lambert J.M., Chari R.V.J. Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer. J. Med. Chem. 2014;57:6949–6964. doi: 10.1021/jm500766w.

Guo, Feng, Junfeng Ke, Zhengdong Fu, Wenzhao Han, et Liping Wang. « Cell Penetrating Peptide-Based Self-Assembly for PD-L1 Targeted Tumor Regression ». International Journal of Molecular Sciences 22, no 24 (10 décembre 2021): 13314. https://doi.org/10.3390/ijms222413314.

Hald Albertsen, Camilla, Jayesh A. Kulkarni, Dominik Witzigmann, Marianne Lind, Karsten Petersson, et Jens B. Simonsen. « The Role of Lipid Components in Lipid Nanoparticles for Vaccines and Gene Therapy ». Advanced Drug Delivery Reviews 188 (septembre 2022): 114416. https://doi.org/10.1016/j.addr.2022.114416.

Frigerio B., Bizzoni C., Jansen G., Leamon C.P., Peters G.J., Low P.S., Matherly L.H., Figini M. Folate receptors and transporters: Biological role and diagnostic/therapeutic targets in cancer and other diseases. J. Exp. Clin. Cancer Res. 2019;38:125. doi: 10.1186/s13046-019-1123-1.

Young O., Ngo N., Lin L.S., Stanbery L., Creeden J.F., Hamouda D., Nemunaitis J. Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors. Curr. Probl. Cancer. 2023;47:100917. doi: 10.1016/j.currproblcancer.2022.100

Liu Y., Dai Z., Wang J., Tu Y., Zhu L. Folate-targeted pH-sensitive bortezomib conjugates for cancer treatment. Chem. Commun. 2019;55:4254–4257. doi: 10.1039/C9CC01344J.

.Ghaffarlou M., Suetekin S.D., Karacaoglu E., Turan S.K., Inci O.G., Gueven O., Barsbay M. Folic acid-modified biocompatible Pullulan/poly(acrylic acid) nanogels for targeted delivery to MCF-7 cancer cells. Eur. J. Pharm. Biopharm. 2023;184:189–201. doi: 10.1016/j.ejpb.2023.02.001.

Li Z.J., Cho C.H. Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery. J. Transl. Med. 2012;10:S1. doi: 10.1186/1479-5876-10-S1-S1

Apostolopoulos V., Bojarska J., Feehan J., Matsoukas J., Wolf W. Smart therapies against global pandemics: A potential of short peptides. Front. Pharmacol. 2022;13:914467. doi: 10.3389/fphar.2022.914467

Adams GP, Weiner LM. (2005). Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147–57. [PubMed] [Google Scholar]

athoni N, Puluhulawa LE, Joni IM, Muchtaridi M, Mohammed AFA, Elamin KM, Milanda T, Gozali D. Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer. Drug Deliv. 2022 Dec;29(1):2959-2970. doi: 10.1080/10717544.2022.2120566. PMID: 36085575; PMCID: PMC9467540.

Kim, Jeonghwan, Yulia Eygeris, Renee C. Ryals, Antony Jozić, et Gaurav Sahay. « Strategies for Non-Viral Vectors Targeting Organs beyond the Liver ». Nature Nanotechnology, 27 décembre 2023. https://doi.org/10.1038/s41565-023-01563-4.

Li, Jianmin, Qingluo Wang, Guoyu Xia, Nigela Adilijiang, Ying Li, Zhenqing Hou, Zhongxiong Fan, et Jinyao Li. « Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy ». Pharmaceutics 15, no 9 (29 août 2023): 2233. https://doi.org/10.3390/pharmaceutics15092233.

Bertrand, N.icolas et al. “Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.” Advanced drug delivery reviews vol. 66 (2014): 2-25. doi:10.1016/j.addr.2013.11.009